Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture.

Tatsunori Miyata, Kazuhiro Sugi,Taichi Horino,Asuka Ono,Yoshiyuki Tagayasu,Daichi Nomoto,Mitsuhiro Inoue,Takao Mizumoto,Tatsuo Kubota,Eriko Yanagida,Toshihiko Murayama,Nobutomo Miyanari,Hideo Baba

Anticancer research（2023）

引用 1|浏览13

暂无评分

摘要

We herein present a case of CS following TAE and Atez+Bev for unresectable and ruptured HCC. The patient did not require chemotherapy after CS and is alive and recurrence-free for 7 months.

查看译文

关键词

Hepatocellular carcinoma,atezolizumab,bevacizumab,conversion surgery,peritoneal metastasis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要